Paolo Gisondi to Male
This is a "connection" page, showing publications Paolo Gisondi has written about Male.
Connection Strength
0.125
-
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. J Allergy Clin Immunol. 2021 Feb; 147(2):558-560.e1.
Score: 0.012
-
Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol. 2020 Jun; 34(6):1196-1201.
Score: 0.012
-
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020 08; 183(2):373-374.
Score: 0.012
-
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. J Am Acad Dermatol. 2020 Jul; 83(1):285-287.
Score: 0.012
-
Image Gallery: Pyoderma gangrenosum of the penis. Br J Dermatol. 2018 01; 178(1):e62.
Score: 0.010
-
Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. Br J Dermatol. 2017 12; 177(6):e325-e326.
Score: 0.010
-
Public perception of dermatology and dermatologists in Italy: results from a population-based national survey. J Eur Acad Dermatol Venereol. 2017 Dec; 31(12):2119-2123.
Score: 0.010
-
Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013 May; 168(5):1124-7.
Score: 0.007
-
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol. 2021 07; 185(1):80-90.
Score: 0.003
-
The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. J Am Acad Dermatol. 2021 05; 84(5):1356-1363.
Score: 0.003
-
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opin Biol Ther. 2021 02; 21(2):271-277.
Score: 0.003
-
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021 01; 147(1):60-71.
Score: 0.003
-
Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. Am J Clin Dermatol. 2020 10; 21(5):749-751.
Score: 0.003
-
Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: The Rotterdam Study. J Am Acad Dermatol. 2021 09; 85(3):671-680.
Score: 0.003
-
Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. Med Ultrason. 2018 May 02; 20(2):177-184.
Score: 0.003
-
Effects of secukinumab on serum adipocytokines: preliminary data. Reumatismo. 2017 Sep 21; 69(3):105-110.
Score: 0.002
-
Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Dermatolog Treat. 2018 May; 29(3):217-219.
Score: 0.002
-
Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series. J Cutan Med Surg. 2017 Nov/Dec; 21(6):502-506.
Score: 0.002
-
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). Br J Dermatol. 2017 Jul; 177(1):197-205.
Score: 0.002
-
Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatol Ther. 2017 Sep; 30(5).
Score: 0.002
-
Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Ann Rheum Dis. 2017 Sep; 76(9):1591-1597.
Score: 0.002
-
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. J Eur Acad Dermatol Venereol. 2017 May; 31(5):863-869.
Score: 0.002
-
Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017 Nov; 31(11):1853-1859.
Score: 0.002